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Abstract
Multidrug resistance (MDR) in cancers is the major challenge in cancer therapy, thus
the development of sensitizing agents or small molecules with new mechanisms of
action to kill the resistant cancers is highly desired. Autophagy is a cellular process
responsible for the turnover of misfolded proteins or damaged organelles and recycling
of nutrients to maintain cellular homeostasis. Recently, autophagy has been shown to
regulate MDR in cancers. In this chapter, both intrinsic and acquired drug resistance
affecting  the  efficiency  of  chemotherapy,  and  the  MDR  mechanisms  including
nonclassical  MDR  phenotype  and  classical  transport-based  MDR  phenotype  were
discussed. In addition, the development of apoptosis-resistant cancer by the deregula-
tion of apoptotic gene machinery, such as BCL-2, BAX, BAK, and TRAILR, was also
covered. We then further discussed the controversial role of autophagy by illustrating
how induction of autophagy could work as a tumor suppressor or promote tumor
survival.  The  modulation  of  MDR  in  cancer  by  either  induction  or  inhibition  of
autophagy was also discussed. We have further summarized the current compounds or
drugs for modulating MDR cancers and how autophagy modulators could circumvent
the MDR phenotypes in cancers. Finally, the new mechanisms participating in MDR
phenotypes were proposed for future MDR drugs discovery.
Keywords: autophagy, multidrug-resistant cancers, apoptosis-resistant cancers, apop-
tosis, P-glycoprotein
1. Introduction
The efficiency of chemotherapy can be affected by both intrinsic and acquired drug resistance.
Intrinsic resistance is caused by the existing resistance factors presented in the cancer cells before
treatments, while acquired drug resistance is developed by mutations or adaptive responses
arising during chemotherapy. Due to the high-molecular heterogeneity of cancer cells, drug
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
resistance can therefore be acquired through a minor population of resistant cancer cells
presented in the initially drug-sensitive tumor. Using the genomic, proteomic, bioinformatics
and systems biology approaches, a wide range of molecular mechanisms, genotypes and
therapeutic targets have been identified in developing drug-resistance cancers. For example,
alterations in drug transport or metabolism, local tumor microenvironment and drug targets
all contribute to chemoresistance. Recently, autophagy has also been identified as an important
mechanism in regulating multidrug resistance (MDR) in cancers [1].
Autophagy is constitutively active in its basal level for maintaining normal homeostasis,
quality control of protein and organelle and working with the ubiquitin proteasomal system
to degrade the polyubiquitinated and aggregated proteins. This catabolic process is triggered
by cellular stressful conditions such as nutrient or energy deprivation, pathogen infection or
misfolded protein accumulation, for the recycle of energy and nutrients to sustain cellular
metabolism. While most evidence supports the prosurvival role of autophagy, unrestrained
autophagy can contribute to cell death resulted from excessive cellular consumption [2]
(Figure 1). Therefore, targeting autophagy for modulating MDR cancers has become an
attractive approach in anticancer therapy.
Figure 1. Cellular function and role of autophagy. Autophagy is a cellular-regulated degradation system for delivering
unwanted cytoplasmic constituents to the lysosome for removal. Autophagy can be triggered by stressful conditions
such as infection, nutrient deprivation or protein aggregates accumulation. Recent studies have depicted the physio-
logical or pathological roles of autophagy in tumorgenesis, neurodegeneration, adaptation to starvation or develop-
ment, clearance of misfolded proteins and organelles, antiaging, elimination of invading pathogens and regulation of
cell death.
2. Autophagy and drug-/apoptosis-resistant cancers
2.1. Molecular mechanism of multidrug resistance in cancers
Drug-resistant mechanisms are classified into two major catergories: (1) nonclassical MDR
phenotype and (2) classical transport-based MDR phenotype. Non-classical MDR refers to the
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decreased sensitivity of tumor to certain anticancer drugs due to the activity of specific
enzymes, including topoisomerase or glutathione S-transferase. Defective apoptotic proteins
may also contribute to the development of drug resistant in tumors. Classical type of transport-
based MDR involves the ATP-binding cassette (ABC) family of transporters, which 49 types
of human ABC transporters were identified. Among them, three ABC transporters were
reported to cause human MDR, including (1) multidrug resistance protein 1 (MDR1/P-
glycoprotein/ABCB1); (2) MDR-associated protein 1 (MRP1/ABCC1); and (3) breast cancer
resistance protein (BCRP/ABCG2), which are responsible for the efflux of several hydrophobic
chemotherapeutic agents such as antimetabolites, taxanes or topoisomerase inhibitors across
the plasma membrane [3].
MDR1, a membrane-bound glycoprotein, which is most abundant on the surface of excretory
epithelial cells of colon, small intestine, pancreatic or bile ductules, and kidney proximal
tubules, was found overexpressed and associated with drug resistance in kidney, liver and
colon cancers. Recently, overexpression of MRP1 has also been found in chemoresistance
breast, prostate and lung cancers. BCRP is a MDR drug efflux pump, which was associated
with drug resistance in leukemia and breast cancer. Chemotherapeutic agents, such as
imatinib, erlotinib, sunitinib and nilotinib, are known substrates and modulators of both MDR1
and BCRP [1].
2.2. “Apoptosis-resistance cancers”
Deregulation of apoptosis can cause drug resistance of cancer cells, and therefore, targeting
the overamplifications, mutations and chromosomal translocations of antiapoptotic proteins,
such as BCL-2 family members, caspase 8 inhibitor FLIP and inhibitor of apoptosis proteins
(IAPs), are important in cancer therapies. Extensive studies suggested the overexpression of
BCL-2 confers resistance of leukemia cells and mouse thymocytes to chemotherapies. Apop-
tosis involving the permeabilization of outer mitochondrial membrane (MOMP) can be
blocked by BCL-2. Antiapoptotic BCL-2 family members, including BCL-XL and MCL1, and
proapoptotic family members, including BAX, BAD, BAK and BH3-only proteins (BIM) which
antagonize the antiapoptotic BCL-2 family members, are key regulators of apoptosis through
the induction of MOMP. Increased expression of BIM is responsible for apoptosis induced by
chemotherapeutic agents, including imatinib, gefitinib and erlotinib, in various cancer models.
Besides, responsiveness to inhibitors of EGFR, HER2 or PI3K is correlated with the level of
BIM. Deletion in the gene-encoding BIM is associated with intrinsic resistance to tyrosine
kinase inhibitors (TKIs) therapies in lung cancer models [1].
Overexpression of prosurvival protein BCL-2 was found in malignant cells with defective
apoptosis; therefore, drugs mimicking its antagonists, BH3-only proteins, may be effective in
chemotherapy. Preclinical data confirmed that both ABT-737 (a BH3 mimetic) and its orally
bioavailable form ABT-263, antagonized the antiapoptotic function of BCL-2, BCL-XL and
BCL-W and exhibited cytotoxicity through Bax/Bak-mediated apoptosis. The weak-binding
affinity of ABT-737 to the antiapoptotic BCL-2 family member (MCL1) can affect the effective-
ness of ABT-737 and lead to drug resistance in cells. Therefore, targeting the enzymatic
Autophagy in Multidrug-Resistant Cancers
http://dx.doi.org/10.5772/64274
437
degradation of antiapoptotic BCL-2 family members may be an alternative way to overcome
the drug resistance in cancer cells [1].
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and agonistic
antibodies targeting the TRAILR death receptors demonstrated antitumor properties in both
in vitro and xenograft models. Currently, combinational use of TRAIL receptor agonists with
chemotherapeutics, including carboplatin, paclitaxel, BCL-2 antagonists, bevacizumab, or
histone deacetylase (HDAC) inhibitors showed prominent effect in clinical evaluations. Several
drugs that are able to improve sensitivity to TRAIL can also decrease the level of the caspase
8 inhibitor (FLIP) and induce apoptosis. Therefore, inhibition of FLIP may work as an attractive
therapeutic strategy for apoptosis-resistance cancers [1, 4].
The small molecule obatoclax (GX15-070) has been reported to antagonize antiapoptotic BCL-2
proteins, such as BCL-2, BCL-XL, BCL-W and MCL-1, and induce both apoptosis and auto-
phagic cell death. Although the molecular mechanisms underlying the effect of obatoclax
remain unclear, both single and combinational therapeutic uses of GX15-070 are under clinical
evaluation, suggesting the role of apoptosis and autophagy in cancer therapy [5].
2.3. Autophagy in tumor suppression
In fact, the role of autophagy in cancer is controversial as it can work as a tumor suppressor,
which inhibits tumor initiation or facilitates the survival of cancer cells during metabolic
stresses induced by anticancer agents. Although autophagy may play a prosurvival role in
tumor cells, loss of function mutations in the autophagy pathways were associated with
tumorgenesis. For example, defects in apoptosis and autophagy may lead to tumorgenesis
through chronic wound-healing response triggered by necrosis and inflammation. Malfunc-
tion of autophagy lead to the mismanagement of metabolic stress, which contributes to damage
of cellular proteins, organelles or DNAs; insufficient ATP levels that are essential for main-
taining normal DNA replication and genomic integrity, all these finally lead to genomic
damage and tumor progression in autophagy-deficient tumor cells. This conception is
supported by evidence of increased DNA breaks or damage response and aneuploidy in
autophagy-defective cancer cells [6] (Figure 2).
Beclin 1 is a haploinsufficient tumor suppressor gene responsible for the induction of autoph-
agy. Overexpression of beclin 1 can inhibit tumorgenesis. Accumulation of the autophagic
substrate, p62/SQSTM 1 protein aggregates, could lead to the damage of mitochondria,
accumulation of misfolded proteins, and overproduction of reactive oxygen species (ROS) that
lead to DNA damage and genomic instability, suggesting the tumor suppressive role of
autophagy [6]. Genetic instability and mutation are causes for increased cancer cells evolution
and resistance to chemotherapy. While autophagy is associated with the promotion of
longevity, DNA damage facilitates both cancer and ageing. Therefore, it is proposed that
autophagy may play a protective role in maintaining cellular and genome stabilities, which
can eventually prevent cancer and extend lifespan [7].
Furthermore, the induction of autophagic cell death has been observed in cancer cells triggered
by excessive activation of autophagy, which causes irreversible damage to cells through
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redundant degradation of regulatory organelles, such as endoplasmic reticulum, mitochondria
and golgi apparatus. Although evidence supporting the anticancer properties of autophagic
death is limited and controversial, induction of autophagic cell death by novel small molecule
activator of autophagy (e.g., STF‐62247) was shown in renal cell carcinoma cells [6]. Proteins
identified to be related to the autophagic cell death included steroid receptor coactivator, foxo1,
histone deacetylases, ras or e4F1. Compound such as dasatinib, an inhibitor of Src/Abl family
kinases, triggers autophagic cell death in ovarian cancer xenograft model; knockdown of
Figure 2. The interplay between autophagy, apoptosis and necrosis in the survival and death mechanisms of cancer
cells. (A) Apoptosis and autophagy are programmed cell death mechanisms involved in various physiological and
pathological conditions such as cancers. Failure in the induction of apoptosis or autophagy could result in malignant
transformation of cells. Despite the basic physiological role of apoptosis and autophagy, targeting both apoptosis and
autophagy pathways has been a popular strategy in chemotherapies. (B) Malfunction of autophagy is frequently found
in human cancers. When apoptosis is inhibited, autophagy is promoted for inducing autophagic cancer cells death.
However, evidence also indicated the induction of autophagy could confer stress tolerance to cancer cells and facili‐
tates the survival of cancer cells under stressful condition, such as starvation, suggesting the controversial role of au‐
tophagy in cancer therapies. (C) The induction of necrotic cell death when both autophagy and apoptosis are inhibited.
Necrosis is referred to the unprogrammed type of cell death characterized by an increase in cell volume and swelling,
which finally lead to the rupture of the cell membrane and burst of cellular contents. (D) Inhibition of cell death is
attributed to DNA damage induced by agents such as cisplatin, which can cause cell cycle arrest and allow the repair‐
ment of damaged cells, and finally lead to multidrug resistance (MDR). Besides, malfunction of apoptosis or induction
of autophagy can also decrease drug‐induced damage of DNA and cell death. All these mechanisms limit the effective‐
ness of chemotherapies via inhibition of specific enzymes or receptors in cells, leading to MDR in cancer cells.
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beclin1 lead to reduction of autophagy and tumor growth. Interestingly, while oncogenic
proteins, such as BCL-2, PI3K or AKT1, could inhibit autophagy, tumor suppressor proteins,
such as beclin1, BIF-1, LKB1 or UVRAG, could induce autophagy. It was reported that
autophagy may inhibit tumors growth by working with apoptosis and/or necrosis to cause cell
death. For example, caffeine induces apoptosis through p70S6K-dependent activation of
autophagy. A novel survivin suppressant, YM155, could induce autophagy-dependent
apoptosis in prostate cancer cells. All these evidence suggested the potential role of autophagy
in cancer therapy [3].
2.4. Inhibition of autophagy in cancer therapy
Increasing preclinical evidence supported the argument that pharmacological inhibition of
autophagy or genetic knockdown of autophagy-related genes (ATGs) can increase sensitiza-
tion of tumor cells to drug-induced cell death. Mechanistic pathways depicting the protective
mechanisms of autophagy in cancers include the E3 ubiquitin ligase c-Cbl cascade that targets
the active Src to promote survival of cancer cells via autophagy. Mutation of oncogene, H-Ras
or K-Ras, upregulates basal autophagy for promoting the survival of cancer cells under nutrient
deprivation conditions. Overexpression of inflammatory receptor, receptor for advanced
glycation end products (RAGE), activated interleukin 6 (IL-6)-mediated mitochondrial
pathway and transcription 3 (STAT3) signaling, induced autophagy and inhibited apoptosis
to promote survival of pancreatic cancer cells. Lymphocyte-induced autophagy triggered
tumorigenesis, suggesting a positive correlation between inflammation and cancer. An
anticancer agent, suberoylanilide hydroxamic acid (SAHA), activated prosurvival autophagic
pathway to attenuate both apoptotic and nonapoptotic cell death, suggesting the inhibition of
autophagy may enhance the efficacy of SAHA [8].
With the prosurvival role of autophagy in cancer treatment, genetic or pharmacological
inhibition on autophagy may therefore enhance the efficacy of cancer therapies. Pharmaco-
logical inhibition of autophagy can be induced by early phrase inhibitors such as 3-methya-
denine (3-MA), wortmannin and LY294002. Late-phrase autophagy inhibitors include
chloroquine (CQ), hydroxychloroquine (HCQ), bafilomycin A1 and monensin. CQ increased
cyclophosphamide-induced cell death of tumor; reduced tumor size and enhanced apoptosis
with the presence of anticancer drug vorinostat in colon cancer xenograft model. Besides, the
treatment of saracatinib (Src inhibitor) with CQ in a prostate cancer mouse model demon-
strated a higher percentage of tumor growth inhibition when compared with saracatinib
alone [6].
Another autophagy inhibitor, 3-MA, enhanced 5-fluorouracil (5-FU)-induced apoptosis with
increased regression of tumor in colon cancer models, suggesting the anticancer properties of
autophagy inhibition in chemotherapy. While combinational use of bortezomib with CQ
suppressed growth of tumor to a greater extent than bortezomib alone in colon cancer models,
evaluation of phase I/II clinical trials is ongoing in patients with myeloma, suggesting the
potential therapeutic use of autophagic inhibitor in cancer therapy [6].
Autophagy in Current Trends in Cellular Physiology and Pathology440
2.5. Role of autophagy in MDR
2.5.1. Inhibition of autophagy in MDR
Overexpression of p-glycoproteins can efflux anticancer drugs and resulted in drug resistance
and failure of anticancer therapies. It has been reported that the induction of autophagy may
contribute to the survival of MDR cells during chemotherapy; defective autophagy contributes
to MDR cells growth inhibition. In contrast, clinical trials have been performed to evaluate the
beneficial role of autophagy enhancer in anticancer therapy, suggesting the double-edged
sword of autophagy which its effect may highly dependent on the stage of tumor. The potent
anticancer and apoptotic properties of gossypol, a BH3-mimetic small molecule isolated from
cottonseeds, have been demonstrated in Ras-NIH 3T3-Mdr cells with overexpression of p-
glycoproteins. However, results indicated that defective autophagy in the Ras-NIH 3T3-Mdr
cells may enhance necrotic and apoptotic cell death induced by gossypol, suggesting the
prosurvival role of autophagy in the MDR cells [9].
Further studies suggested that autophagy may contribute to resistance to chemotherapy drugs,
such as tamoxifen, herceptin, paclitaxel (PTX) and epirubicin (EPI), in breast cancer. It was
demonstrated that PTX- and vinorelbine (NVB)-induced autophagy facilitated the develop-
ment of resistance to PTX and NVB in both MCF-7er and SK-BR-3er cells with overexpression
of p-glycoproteins. The finding suggested that the use of autophagy inhibitors may be an
attractive way for overcoming MDR in cancer therapy [10]. Further evidence suggested that
the combinational use of autophagy and Src tyrosine kinase inhibitor was able to sensitize
MDR cells to anticancer therapy. To increase the therapeutic efficacy of 5-fluorouracil (5-FU)
to MDR colon cancer cells, many reports have confirmed the use of autophagy inhibitors, such
as 3-MA or chloroquine, can increase the sensitivity of cancer cells toward treatment of 5-FU.
2.5.2. Activation of autophagy in MDR
Although mitigating MDR through inhibition of ABC transporter-mediated drug efflux or
autophagy may be an effective approach in anticancer therapy, the induction of autophagy
may also attenuate MDR. For example, vocamine (alkaloid) isolated from Peschiera fuchsiaefolia
can mitigate drug resistance of osteosarcoma cells by inhibiting p-glycoproteins and inducing
autophagic cell death when used with chemotherapeutic agent doxorubicin. Autophagy
increases the efficacy of radiation therapy in both apoptosis-deficient lung cancer cells and
xenograft model. Evidence demonstrating the potential anticancer efficacy of mTOR inhibitors
was abundant. For example, combinational treatment by beclin1 expression and autophagic
induction inhibited the growth of MDR (Ras-NIH 3T3) cells. Interestingly, constitutive
expression of p-glycoproteins in hepatocellular cancer cells can lead to overexpression of BCL2
and mTOR, which contributed to resistance of cells to both apoptosis and autophagy [3].
In fact, autophagic cell death was observed in a p-glycoproteins overexpressing breast cancer
cells that are resistant to paclitaxel. Further report demonstrated that long-term exposure to
cisplatin leads to MDR and finally inhibition of both cisplatin-mediated apoptotic cell death
and autophagy. Consistently, the presence of autophagic inducer can mitigate the resistance
of cancer cells toward cisplatin-mediated apoptotic cell death, suggesting the anticancer
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property of autophagy induction. p53, a well-known tumor suppressor gene, can lead to cancer
cell death. Mutations in p53 were highly correlated with failure of chemotherapy or radio-
therapy. However, while p53 mutant utilizes autophagy to kill the ovarian MDR cancer cells,
wild-type p53 reverses the MDR phenotype by autophagy inhibition. The observation has
further suggested the dual role of autophagy in MDR cancer therapy, and special cautions are
required when applying autophagy modulators in cancer therapies [3].
3. Current approaches, challenges and compounds in targeting MDR
3.1. Current compounds/drugs in modulating MDR cancers
Malfunction of the apoptosis contributed to the survival of cancer cells under oxidative stress
and hypoxia conditions. These lead to the accumulation of genetic defects in cells, which
resulted in the deregulation of cell proliferation or promotion of angiogenesis during tumor-
genesis. Therapeutic strategies targeting apoptosis through inhibition of antiapoptotic
proteins or stimulation of expression of proapoptotic proteins have been used in anti-MDR
cancer treatments. In fact, mutation or alteration in the level of drug targets may also confer
resistance to therapeutic agents in cancer cells. For example, fluoropyrimidine 5-fluorouracil
(5-FU), a common chemotherapeutic agent for breast and colorectal cancers, triggers cancer
cell death via inhibition of thymidylate synthase (TS) [11]. Consistently, many evidences
suggest that high expression of TS contributed to the increase resistance of cancer cells to 5-
FU. Another type of chemotherapeutic agents, including paclitaxel, docetaxel, vinblastine and
vincristine (vinca alkaloids), inhibited tumor growth via suppressing the polymerization of
microtubules, and eventually lead to apoptotic cell death. However, cancer cells can acquire
resistance to paclitaxel or vinca alkaloids by alternating the levels of tubulin isotypes, since a
reduction in tubulin levels was found in paclitaxel-resistant cells. Platinum-induced DNA
damage by cisplatin can trigger apoptosis. While an increase in the BAX to BCL-2 ratio by
cisplatin could induce apoptosis, overexpression of BCL-2 was reported in tumors that were
resistance to cisplatin. Therefore, functional defects in the apoptotic pathway or inactivation
of apoptosis may contribute to the development of drug resistance in cancers and revealed the
current challenges of using chemotherapeutic agents in MDR cancer therapies [12].
New therapeutics against specific antiapoptotic targets has been applied to enhance apoptosis
and sensitize MDR cancer cells to anticancer agents. For example, antiestrogens, such as
tamoxifen, can inhibit estrogen-dependent BCL-2 expression and increase the sensitivity of
cancer cells to anticancer agent doxorubicin. Expression of BCL-2 or BCL-XL can be downre-
gulated by small molecule compounds regulating retinoic acid receptors (RAR), PPAR or
retinoid receptors. For example, RAR and RXR ligands are used to treat leukemia and
lymphoma in clinical trials; PPAR agonist troglitazone, decreased serum prostate-specific
antigen (PSA) in patients with prostate cancer; inhibitors of histone deactylases (HDACs) can
suppress the expression of antiapoptotic BCL-2-family genes in cancers and enhance sensitiv-
ity of cancer cells to conventional cytotoxic agents in xenograft models or clinical trials.
Moreover, antisense oligonucleotides targeting the BCL-2 mRNA are in phase III clinical trials.
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BH3-only proteins, endogenous antagonists targeting BCL-2 and MCL-1, have been revealed
for their therapeutic potency to induce apoptosis. The anticancer effect of synthetic BH3
peptides occupying the BH3-binding site of BCL-2 or BCL-XL, and BH3-mimicking com-
pounds have already been validated for their anticancer properties. Small molecule BCL-2
inhibitors (HA14-1), BH3 peptidomimetics and BCL-2 antagonists (ABT-737 and ABT-263)
have been shown in the preclinical studies to enhance the sensitivity of cancer cells to ionizing
radiation or chemotherapeutic agents, providing us an overview on current approach of
targeting apoptosis in MDR cancer therapies [12].
Overcoming intrinsic apoptosis failure during anticancer therapies could be achieved by
triggering extrinsic apoptosis. For example, TNF treatment by cytokines FasL and TRAIL can
activate caspases without the proinflammatory activation of the NF-KappaB pathways. TRAIL
and its agonistic antibodies that bind TRAIL receptors have been proved to possess potent
antitumor effect in mouse xenograft models. Moreover, clinical trials evaluating the efficacy
of agonistic antibodies were completed, suggesting the potential of applying these biological
agents to circumvent the defective intrinsic mitochondrial apoptotic pathway. CDDO and
CDDOm are synthetic triterpenoids that sensitize cells to TRAIL-induced apoptosis in
chemoresistant leukemia cells. Byrostatin, a protein kinase C (PKC) modulator, triggers the
production of TNF and apoptosis in myeloid leukemia cells. All-trans-retinoic acid (ATRA)
induces the production of cytokine TRAIL and apoptosis in acute leukemia cells, confirming
the beneficial role of targeting TRAIL to kill cancer cells that are resistance to apoptosis. Heat-
shock protein 90 (Hsp90) is a molecular chaperone ubiquitously expressed for the maturation
of a set of substrate proteins called clients. Hsp90 promotes invasion, angiogenesis and
metastasis which all contribute to tumorgenesis. Hsp90 stabilizes Raf-1, Akt and ErbB2
proteins and lead to the resistance of cancer cells to radiation therapy. Geldanamycin, inhibitor
of Hsp90, enhances the sensitivity of cancer cells to radiation therapy. However, due to the
poor solubility, high toxicity and problems of drug efflux by p-glycoprotein, modification on
synthetic Hsp90 inhibitors has been made. For example, pyrazole resorcinol compound NVP-
AUY922 has higher binding affinity to Hsp90, and NVP-BEP800, a 2-aminothieno pyrimidine
class Hsp90 inhibitor, possess high antiproliferative activity in cancer cells. These inhibitors
increase the sensitivity of tumor cells to apoptosis via depletion and destabilization of Hsp90
proteins and finally lead to increased DNA damage and apoptosis [12].
3.2. Current compounds/drugs regulating MDR cancers through autophagy
Most, if not all, chemoresistant cancers have defects in apoptotic pathways. In addition, the
mitochondrial/cytochrome c pathway of apoptosis is frequently perturbed in various types of
human cancers [13]. For instance, gene deficiency of BAX or BAK is commonly found in many
malignancies, and BAX-BAK double-knockout mouse embryonic fibroblasts (MEFs) are
resistant to various apoptosis-inducing agents [14]. On the other hand, caspase-3 and caspase-7
are crucial mediators of mitochondrial-mediated apoptosis [15], whereas caspase-3, caspase-8
and caspase-9 contribute the signal transduction roles in apoptosis induced by anticancer
agents. Deficiency of these caspases would ultimately develop apoptosis-resistance and drug
resistance phenotypes [16]. Although autophagy is considered as a crucial player in drug
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resistance because cancer cells can circumvent cellular stress via autophagy induction, it has
been shown that autophagy facilitates resistance of cancer cells to chemotherapeutic agents,
and inhibition of autophagy could be therapeutically beneficial in some cases [17].
Nevertheless, significant number of studies demonstrated that the use of small molecules to
induce autophagy-dependent cell death in apoptosis-defective or apoptosis-resistant cancer
cells is an effective therapeutic approach [18]. These evidences are fuelling novel approaches
to treat cancer and impede multidrug resistant through the induction of autophagy (Table 1).
Compounds or
drugs
Sources Target pathways Autophagy
inducer or
inhibitor
Types of MDR  Origin of
cancers
References
Saikosaponin-d
(Ssd)
Bupleurum
falcatum L
SERCA Inducer Caspases 3, 7 or  
8 deficient
Bax-Bak DKO
MEFs [19]
Liensinine,
isoliensinine,
dauricine,
cepharanthine
Nelumbo nucifera,
Asiatic moonseed
rhizome, Stephania
cepharantha
AMPK-mTOR Inducer Caspases 3, 7 or
8 deficient
Bax-Bak DKO
MEFs [20]
Hernandezine Thalictrum
glandulosissimum
AMPK Inducer Caspases 3, 7 or
8 deficient
Bax-Bak DKO
MEFs,
colon
[21]
Ursolic acid Apple peels JNK signaling Inducer p53 mutation Colorectal
cancer
[22]
Rottlerin Kamala powder unknown Inducer Caspase 3
deficient
Breast
cancer
[23]
Coibamide A Marine
cyanobacterium
mTOR-
independent
Inducer Apaf-1-null MEFs,
glioblas
toma
[24]
Chalcone-24 Synthetic c-FLIPL and
c-IAPs
degradation 
Inducer TRAIL
resistant
Lung
cancer
[25]
PG545 Synthetic Heparanase Inhibitor Heparanase-
overexpressing
cancer
Cancer
cells
[27]
Nelfinavir FDA drug Unfolded
protein
response
(UPR) and
endoplasmic
reticulum
Inducer Doxorubicin
resistant
Breast
cancer
[28]
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Compounds or
drugs
Sources Target pathways Autophagy
inducer or
inhibitor
Types of MDR  Origin of
cancers
References
(ER) stress    
Rapamycin FDA drug mTOR, mdr1
expression
Inducer Doxorubicin
resistant
Colon
cancer
[29]
Lansoprazole Synthetic Proton pump Inhibitor Doxorubicin
resistant
Solid
tumors
[30]
Oxaliplatin
derivatives
with axial
DCA ligands
Synthetic Mitochondria
and glucose
metabolism 
Inducer Cisplatin
resistant
Colorectal
cancer
[31]
LY294002 and
rapamycin
Synthetic and
FDA drug
Akt/mTOR
signaling,
miR-222
Inducer Cisplatin
resistant
Bladder
cancer
[32]
Rapamycin FDA drug mTOR Inducer Cisplatin
resistant
Cervical
cancer
[33]
Ursodeoxycholic
acid
Synthetic CD95/Fas Inducer Cisplatin
resistant
Gastric
cancer
[34]
Monanchocidin A Marine sponge
Monanchora
pulchra
Lysosomal
membrane
permeabilization
Inducer Cisplatin
resistant
Germ
cell tumor,
prostate
and bladder
cancer
[35]
Resveratrol
derivative, TMS
Synthetic SERCA Inducer Gefitinb
resistant
NSCLC
cells
[36]
Chloroquine FDA drug Autophagy Inhibitor Gefitinb
resistant
Liver
cancer
[37]
Leu-Leu-O-
methyl
Synthetic Lysosome
membranes
Inhibitor Sunitinib
resistant
Renal
carcinoma
[39]
Metformin FDA drug GRP78 Inhibitor Bortezomib
resistant
Multiple
myeloma
[40]
Table 1. Current compounds or drugs targeting MDR through modulation of autophagy.
In fact, the active components isolated from natural products have been found effective in
inducing autophagic cell death or autophagy-dependent cell death in apoptosis resistance cells
or cancers. For example, saikosaponin-d (Ssd), extracted from Chinese medicinal herb
Bupleurum falcatum L., is capable of inducing autophagic cell death in a panel of apoptosis-
resistant cells [19]. Ssd increases cytosolic calcium via direct suppression of sarcoplasmic/
endoplasmic reticulum Ca2+ ATPase Pump (SERCA), leading to autophagy induction through
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the activation of the Ca2+/calmodulin-dependent kinase kinase (CaMKK)—AMP-activated
protein kinase (AMPK)—mammalian target of rapamycin (mTOR) pathway. Importantly, Ssd-
disrupted calcium homeostasis stimulates endoplasmic reticulum (ER) stress as well as the
unfolded protein responses (UPR) and eventually contributes to autophagic cell death in
apoptosis-defective or apoptosis-resistant mouse embryonic fibroblasts (MEFs), which either
lack caspases 3, 7 or 8 or had the BAX-BAK double knockout [19]. Concomitantly, a group of
natural alkaloids, including liensinine (Nelumbo nucifera), isoliensinine (Nelumbo nucifera),
dauricine (Asiatic Moonseed Rhizome) and cepharanthine (Stephania cepharantha), were identified
to stimulate AMPK-mTOR-dependent induction of autophagy and autophagic cell death in
the same panel of apoptosis-resistant cell [20]. These alkaloids were later confirmed as novel
and direct AMPK activators [21]. Furthermore, hernandezine, an alkaloid isolated from
Chinese medicinal herb Thalictrum glandulosissimum, sharing structural similarity with the
above isoquinoline alkaloids, exhibits specific cytotoxicity and induces autophagy in a panel
of cancer cells. Hernandezine is a new class of AMPK activator, which induces autophagy and
autophagic cell death in a panel of caspases-deficient apoptosis-resistant MEF. Those studies
further indicated that the MEFs with genes deficiency of BAX and BAK demonstrated drug-
resistant phenotypes in various chemotherapeutic agents, such as cisplatin, adriamycin, taxol,
etoposide and staurosporine, but not in hernandezine. And hernandezine also shows similar
cytotoxicity toward both wild type and double knockout of BAX/BAK in human DLD-1 colon
cancer cells, suggesting the cross sensitivity of hernandezine toward this apoptosis-deficient
cancer [21].
Apart from AMPK-mTOR signaling, mutations of tumor suppressor p53 have been shown to
confer cellular resistant to various chemotherapeutic agents. For instance, colorectal carcino-
mas (CRCs) with p53 mutations have developed resistance to widely used chemotherapeutic
agent, 5-fluorouracil (5-FU) [22]. A natural triterpenoid, ursolic acid, was found to sensitize
p53 mutant apoptosis-resistant colorectal cancer cells to 5-FU effects via activation of c-jun N-
terminal kinase (JNK) [22]. In addition, rottlerin, a natural polyphenol purified from the
kamala powder, induces autophagic death in caspase-3−/− apoptosis-resistant MCF-7 breast
cancer cells [23]. Coibamide A, an N-methyl-stabilized depsipeptide isolated from a marine
cyanobacterium, induces autophagy and cell death in apoptosis-resistant MEFs and glioblas-
toma cells [24]. Other synthetic compounds and derivatives can overcome chemoresistance by
modulation of autophagy. For instance, a novel chalcone derivative, chalcone-24, potentiates
the anticancer activity of TNF-related apoptosis-inducing ligand (TRAIL) through autophagy-
mediated degradation of cellular FADD-like IL-1β-converting enzyme-inhibitory protein large
(c-FLIPL) and cellular inhibitor of apoptosis proteins (c-IAPs), which could be an effective
approach in alleviating drug resistance [25]. Besides, sepantronium bromide (YM155) is a
selective survivin inhibitor that exhibits potent antitumor activities in head neck squamous
cell carcinoma (HNSCC) in vitro and in vivo by inducing apoptosis and autophagic cell death
[26]. On the other hand, heparanase is a mammalian enzyme capable of cleaving heparan
sulfate, whose enzymatic activity contributed to tumor inflammation, angiogenesis and
metastasis. Recent studies indicated that heparanase-overexpressing cancers were more
resistant to chemotherapy in a manner associated with increased autophagy, and therefore,
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the suppression of heparanase and its mediated autophagy by heparanase inhibitor (PG545)
is a promising strategy in treatment of these resistant cancers [27].
Several clinically approved drugs were found to be effective in treating doxorubicin‐resistant
cancer cells through modulation of autophagy. For example, nelfinavir, a clinically approved
anti‐HIV drug targets multidrug‐resistant mechanism to enhance the efficacy of doxorubicin
in doxorubicin‐resistant MCF‐7 breast cancer cells [28]. Rapamycin, a mTOR inhibitor, reverses
drug resistance to doxorubicin in colon cancer through induction of autophagy and apoptosis,
and suppression of multidrug resistance gene 1 (mdr1) expression [29]. Proton pump inhibitor
lansoprazole potentiates the therapeutic effects of doxorubicin by improving its distribution
and activity in solid tumors [30].
In cisplatin‐resistant cancer, study reported that oxaliplatin derivatives with axial dichloroa‐
cetate (DCA) ligands induce autophagy and potentiate toxicity in cancer cells through
modulation of mitochondria and glucose metabolism. These derivatives can also overcome
inherent and acquired resistance to cisplatin and oxaliplatin [31]. Inhibition of Akt/mTOR
signaling by LY294002 and rapamycin prevents miR‐222‐induced proliferation and restores
the sensitivity of resistant bladder cancer cells to cisplatin. These findings indicated that
miR‐222 activates the protein phosphatase 2A subunit B/Akt/mTOR axis and thus plays a
critical role in regulating proliferation and chemotherapeutic drug resistance [32]. Consistent‐
ly, cisplatin cytotoxicity could be greatly enhanced in resistant cancer cells when mTOR had
been inhibited prior to cisplatin treatment that was likely due to increased autophagy level
[33]. Ursodeoxycholic acid effectively kills drug‐resistant gastric cancer cell through induction
of autophagic death [34]. Besides, a novel alkaloid, monanchocidin A isolated from the marine
sponge Monanchora pulchra, overcomes drug resistance by induction of autophagy and
lysosomal membrane permeabilization [35].
In other drugs‐resistant cancers, a new analogue of resveratrol, (Z)3,4,5,4′‐trans‐tetramethox‐
ystilbene (TMS), inhibits gefitinib‐resistant non‐small cell lung cancer (NSCLC) through
inhibition of SERCA and induction of autophagy [36]. In contrast, co‐delivery of gefitinib and
chloroquine by chitosan nanoparticles overcomes gefitinb‐resistant liver cancer by the
inhibition of gefitinib‐mediated autophagy [37]. Similarly, inhibition of lapatinib‐mediated
protective autophagy sensitizes HER2‐positive breast resistance cancer cells to lapatinib,
suggesting that autophagy is a promising target for circumventing lapatinib resistance of
HER2‐positive breast cancer cell [38]. Inhibition of sunitinib‐mediated autophagy overcomes
sunitinib resistance in metastatic renal cell carcinomas [39]. Similarly, metformin suppresses
glucose‐regulated protein 78 (GRP78), a key driver of bortezomib‐induced autophagy and
enhances the antimyeloma effect of bortezomib [40].
Collectively, MDR cancer cells defective in apoptosis signaling pathway are more sensitive to
various types of autophagy inducers, which eventually induce autophagy‐associated cell
death or autophagic cell death. It is suggested that autophagy and its associated cell death
provide an alternative promising approach for inducing cell death in MDR cancers. However,
both autophagy inducers and inhibitors are commonly involved in the suppression of many
other drugs‐specific MDR cancer cells. Understanding the role of autophagy in particular
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chemotherapeutic treatment is crucial for establishing an effective treatment of MDR via
modulation of autophagy.
4. New mechanisms participating in MDR phenotypes for future drug
discovery
Heme oxygenase-1 (HO-1) contributes to imatinib resistance by promoting autophagy in
chronic myeloid leukemia through disrupting the mTOR-signaling pathway [41], whereas Src/
STAT3-dependent HO-1 induction contributes to doxorubicin resistance in breast cancer cells
by promoting autophagy [42]. Thus, HO-1 may be a novel target for improving MDR pheno-
types in leukemia and breast cancer therapy. Galectin-1 is a beta-galactoside-binding lectin,
and its mediated autophagy facilitates cisplatin resistance of hepatocellular carcinoma (HCC).
Thus, galectin-1 may be a potential target to improve the efficacy of cisplatin in the treatment
of patients with HCC [43]. Other studies showed that activation of autophagy in tumor
associated macrophages (TAMs) inhibits proliferation and induces apoptosis in colon cancer
cells and alters the expression of radiosensitivity associated proteins. Therefore, stimulating
TAM autophagy may increase the radiosensitivity of colorectal cancer cells [44]. BRAF is an
oncogenic protein, which promotes protective autophagy in colorectal tumor cells.
BRAFV600E is the mutant protein of BRAF, which contributes to the drug-resistant phenotype
of colorectal tumors. Study showed that pretreatment of autophagy inhibitor 3-MA followed
by combinational treatment with drug PLX4720 targeting BRAFV600E can synergistically
sensitize resistant colorectal tumors and provide novel efficient approaches for the treatment
of resistant colorectal tumors bearing BRAFV600E [45]. The CD44 isoform-containing variant
exon v6 (CD44v6) exhibits a crucial role in the progression, metastasis and prognosis of
colorectal cancer. Overexpression of CD44v6 contributes to acquired chemoresistance via
upregulation of autophagy in colon cancer SW480 cells, indicating that CD44v6 may be the
new therapeutic target for resistant colorectal cancer [46].
Early growth response gene-1 (Egr-1) enhances hypoxia-induced autophagy to contribute
chemoresistance of HCC. Dominant negative Egr-1 inhibits autophagy and thus enhances the
sensitivity of HCC cells to chemotherapeutic agents, indicating that hypoxia/Egr-1/autophagy
axis might be a novel therapeutic target for improving drug resistance in HCC [47]. Urothelial
carcinoma is characterized by therapeutic resistance and frequent tumor relapse. Study
indicated that the synergistic cytotoxic effect of gemcitabine/mitomycin with autophagy
inhibitor (chloroquine) or with glycolytic inhibitor (2-deoxyglucose) may be of help in
improving the treatment outcome in patients with urothelial carcinoma [48]. Blockage of
prosurvival autophagy by TGF-β inhibition in bone marrow fibroblasts circumvents bortezo-
mib resistance in patients with multiple myeloma. Therefore, a combinational treatment of
bortezomib and TGF-β inhibitor may provide the basis for a novel targeted therapeutic
approach [49]. Metabolic reprogramming by activation of glutaminolysis induces resistance
to anti-NOTCH1 therapies in T-cell acute lymphoblastic leukemia (T-ALL). Suppression of
both glutaminolysis and autophagy synergistically potentiate the antileukemic effects of anti-
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NOTCH1 therapy in mice harboring T-ALL, suggesting glutaminolysis as a novel therapeutic
target for the treatment of T-ALL [50].
5. Conclusion
This chapter, with the main focus on the role of autophagy in multidrug-resistant cancers, has
demonstrated the controversial role of autophagy in cellular mechanisms of defense against
cancers and immunochemical homeostasis. Autophagy, a cellular process responsible for the
turnover of misfolded proteins or damaged organelles, is important key mechanism for
recycling of nutrients to maintain normal cellular homeostasis, DNA replication and genomic
integrity. This prevents the overproduction of metabolic stress that contributes to damage of
cellular proteins, organelles or DNAs, which finally lead to genomic damage and tumor
progression in cells. This conception is supported by our listed evidence of increasing number
of novel autophagic small molecules that could circumvent the MDR phenotypes in cancers
via cellular regulation of autophagy. This chapter has therefore given a comprehensive
summary on the role of autophagy or autophagic enhancers/ inhibitors in the cellular
mechanisms of defence and homeostasis in cancers.
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